A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
<i>Candida</i> spp. are the fourth on the list of sepsis pathogens in patients in intensive care units. Currently the physician's armamentarium includes a whole range of antifungal medicines that have demonstrated high clinical-mycological effectiveness in clinical trials. The aim of this study to evaluate the clinical-economic usefulness of caspofungin therapy in the treatment of invasive candidiasis versus standard and alternative treatments in patients in intensive care units. The first time in the Russian clinical-economic analysis for targeted IC treatment in non-neutropenic patients in intensive care units who have not received primary prophylaxis with azole antimycotics, as well as in those with low (< 20%) occurrence of in vitro <i>Candida</i> spp. resistance to fluconazole according to national or local study results, yielded the following findings: the best strategy is initial amphotericin B therapy with subsequent switching to caspofungin in patients with ineffective initial amphotericin B therapy or those with severe adverse events.